Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Clinical trial NCT03010982 · COMPLETED
Trial details
- NCT number
- NCT03010982
- Sponsor
- Epizyme, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-20
- Primary completion
- 2019-01-08
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.